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Abstract: The effects of 5,10-Methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism on human bone marrow-derived
mesenchymal stem cells (hBM-MSCs) viability, morphology, physiology and differentiation capacity were investigated in this study.
For this purpose, primary hBM-MSCs with wild type (WT, C/C), heterozygote (HTZ, C/T) and homozygote (HMZ, T/T) for the
MTHFR gene were obtained with ethical committee permission and donor informed. Mutations were detected using RFLP and Sanger
sequencing methods from genomic DNA isolated from cells, colonization properties were investigated by CFU-F test and proliferative
differences were investigated by MTT test. Adipogenic, osteogenic, and chondrogenic differentiation were induced to study changes in
their differentiation potentials, and the results were statistically analyzed using one-way ANOVA with Graphpad Prism. A total of 13
donors were screened and there were no differences in the hBM-MSC markers and in vitro morphologies of the cells. While there were
significant differences between WT and HTZ as a result of the CFU-F test, there were no significant differences in the MTT test after 24
and 48 h. As a result of differentiation tests, it was found that adipogenic differentiation was significantly more in HMZ cells than WT
cells. Osteogenic and chondrogenic differentiation results did not give statistically significant results. As a result of these experiments,
adipogenic differentiation was found to be affected by the MTHFR genotype in hBM-MSCs.
Key words: 5,10-Methyltetrahydrofolate reductase (MTHFR), human bone marrow-derived mesenchymal stem cells (hBM-MSCs),
C677T, polymorphism, adipocyte, differentiation

1. Introduction
5,10- Methyltetrahydrofolate reductase (MTHFR) enzyme
is involved in folate metabolism, which regulates DNA,
RNA and protein methylation of cell metabolism. MTHFR
converts 5,10- methyltetrahydrate to 5-methyltetrahydrate.
5-methyltetrahydrofolate produced in this way acts as
a methyl donor for the conversion of homocysteine to
methionine (Goyette et al., 1998). This transformation is
catalyzed by the enzyme methionine synthase found in all
mammalian tissues and vitamin B12 is used as a cofactor
(Günebak Şahin ÇT, 2012). Therefore, all mutations
in the MTHFR gene that alter enzyme function cause
deterioration in the pathways of methylation and DNA
synthesis. The most common mutation in the MTHFR
gene is C677T polymorphism. This polymorphism is
located in exon 4 and results in the conversion of Valin
amino acid to Alanine amino acid in the codon 222

region. C677T polymorphism alters the thermostability
of the enzyme produced, causing its activity to decrease
(Rosenberg et al., 2002).
According to the literature, MTHFR C677T
polymorphism has been associated with many different
types of diseases. There are cardiovascular diseases such
as stroke (Banerjee et al., 2007), coronary artery diseases
(Verhoef et al., 2002), infertility and pregnancy loss (Cao
et al., 2013; Rai and Kumar, 2017), down syndrome (Rai et
al., 2014), diseases associated with pregnancy such as Spina
Bifida (Shaw et al., 1999), neurological and psychiatric
problems such as Parkinson’s, Alzheimer’s, schizophrenia
(Hua et al., 2011; Wu et al., 2013; Hu et al., 2015), diabetic
neuropathy (Yang et al., 2013), many different types of
cancer (Ergul et al., 2003 ; Izmirli et al., 2011; Küçükhüseyin
et al., 2011; López-cortés et al., 2013; Ozen et al., 2014; Xu
et al., 2013), bone-related diseases such as osteoporosis
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(Villadsen et al., 2005) and autoimmune diseases such as
Behçet disease (Özkul et al., 2005). The common presence
of C677T polymorphism in the MTHFR gene in all these
different types of diseases demonstrates the importance of
this gene and related mutation. Christensen et al. (1997)
reported in animal studies that this enzyme can show the
activity of around 40% in homozygous individuals, and
around 60% in heterozygous.
Mesenchymal stem cells (MSCs) are adult stem cell
types whose therapeutic use in regenerative medicine and
tissue engineering is quite common and valuable. These
cells have the potential to transform into many different
cell types such as osteocyte (bone cell), adipocyte (fat cell),
and chondrocyte (cartilage cell) (Kolios and Moodley,
2012). Although MSCs can be isolated from many different
regions such as adipose tissue, amniotic fluid, peripheral
blood, the most commonly used type of mesenchymal
cells is isolated from bone marrow (bone marrow-derived
mesenchymal stem cells, BM-MSCs) (Ding et al., 2011).
Because of MTHFR C677T polymorphism,
homocysteine levels increase. High homocysteine level
is considered as an indicator for bone and heart diseases,
and trigger the formation of osteoclasts, causing a decrease
in bone density (Behera et al., 2017). Another study has
shown that high concentrations of homocysteine cause
apoptosis in BM-MSCs (Cai et al., 2013). Behçet’s disease
is also associated with MTHFR C677T polymorphism.
Davatchi et al. (2013) studied the regenerative capacities of
autologous MSCs in the treatment of vasculitis occurring
due to Behçet’s disease and it was examined to see if
there was a change in their eyesight. However, this study,
which was carried on three patients, it was concluded
that there was no improvement in their eyesight and that
stem cell therapy was unsuccessful (Davatchi et al., 2013).
In another Behçet disease study, the significant decrease
in central nervous system damage was observed when
allogeneic MSCs were given to a patient with central
nervous system damage (Marmont et al., 2006). The most
important difference that stands out in these two studies is
the genetic infrastructure of the MSCs used. This suggests
that genetic changes that are effective in Behçet’s disease
may be acting upon the differentiation and regeneration
capacity of MSCs.
MSCs can be transferred to the body, in regenerative
applications for the cellular treatment, either by autologous
or allogeneic transplantation in order to repair the damaged
tissue. This research study aimed to investigate the effects
of MTHFR C677T polymorphism on the differentiation
capacities, vitality, clonality and morphology of hBMMSCs obtained from real donors and according to our
results, MTHFR C677T homozygous polymorphism
affects the CFU-F and adipogenic differentiation capacities
of hBM-MSCs.
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2. Materials and methods
2.1. Cells and their maintenance
Primary hBM-MSCs were obtained from Acıbadem
Labcell and used in this research study with ethical
approval of Acıbadem Mehmet Ali Aydınlar University
ethics committee, with ATADEK 2019/1-13 approval
number.
hBM-MSCs were plated on cell culture plates covered
with 0.1% Gelatin (Sigma, 9391) and cultured in MSC
Nutristem XF medium (Biological Industries, 05-2001A) supplemented with MSC Nutristem XF Supplement,
in 37 °C, 5% CO2 incubator. The medium was changed
every 2–3 days till the cells reached 80% confluency and
passaged 1:4 by using 0.05% 1X Trypsin EDTA (Gibco,
25300054).
2.2. DNA isolation
For DNA isolation, 1 × 106 of BM-MSC were incubated
in 300 uL lysis buffer containing 240 ug proteinase K at
55 °C for 1.5 h by agitation. One hundred microliters of
5M NaCl solution was added and kept on ice for 10 min.
Samples were centrifuged at 4 °C, 3000 rpm for 30 min and
the supernatant is treated with 800 uL of isopropanol at RT
for 15 min. Tubes were centrifuged at RT with 13,000 rpm
for 10 min. One milliliter of 70% EtOH was added onto
the pellet and the tubes were washed by inverting gently.
After washing, it was centrifuged at RT and maximum
rpm for 10 min. EtOH was removed from the tubes
and then they were kept upside down until EtOH was
completely evaporated. DNA samples were dissolved in
100 uL of ddH2O and their concentration was determined
by Nanodrop.
2.3. Mutation determination
Restriction fragment length polymorphism (RFLP) assay
was performed in order to determine C>T mutation on
MTHFR gene. Primers that amplified for all genes were
designed by using Primer Blast (NCBI) (Table 1.1). A
total of 100 ng of DNA obtained from BM-MSCs, the 389
bp region surrounding the mutation were amplified by
polymerase chain reaction (PCR) (T100 Thermal Cycler,
BioRad, 1801096) (Tables 1.2 and 1.3). The C>T mutation
creates a recognition site for the HinfI restriction enzyme.
Since there is a Hinf1 recognition sequence in the amplified
region of the BNP gene, it was used as a positive control
in all reactions. The amplified region was cleaved by HinfI
enzyme for 1 h at 37 °C (T100 Thermal Cycler, BioRad,
1801096) (Table 1.4). The expectation for the enzyme
cleavage was a single band (389bp) in wild type (WT) BMMSCs which carry no mutation, two bands (173 bp and
217 bp) in the homozygous mutant (HMZ) BM-MSCs and
three bands (389 bp, 173bp and 217 bp) in heterozygous
mutant (HTZ) BM-MSCs.
Following the RFLP assay, PCR amplicons were also
subjected to Sanger sequencing, simultaneously in order
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Table 1.1. PCR primer sequences.
Primer name

Primer sequences (5’-3’)

MTHFR-Forward

ACTCAGCGAACTCAGCACTC

MTHFR-Reverse

AGAGGACTCTCTCTGCCCAG

BNP-Forward

CAGCCTCGGACTTGGAAAC

BNP-Reverse

CTTCCAGACACCTGTGGGAC

Table 1.2. PCR conditions for amplification.
Component

50 uL reaction

5x My Taq Buffer (Bioline)

10 uL

MTHFR/BNP primers (F/R) 2 uL
My Taq DNA polymerase

1 uL

ddH2O

Up to 50 uL
Volume determined depending
on stock gDNA concentration

100 ng DNA

Table 1.3. Thermal cycler conditions of PCR.
BNP

MTHFR

Initial denaturation

95 °C, 4min

95 °C, 4 min

Denaturation

95 °C, 30 s

95 °C, 30 s

Annealing

60 °C, 30 s

60 °C, 30 s

Extension

68 °C, 30 s

68 °C, 30 s

Cycles

35

35

Final extension

68 °C, 5 min

68 °C, 5 min

Table 1.4. RFLP conditions.
For 50 uL of PCR product
Uncut

Cut

CutSmart Buffer

2.5 uL

2.5 uL

Hinf1 enzyme

-

0.5 uL (U)

ddH20

2.5 uL

2 uL

to confirm the results. Sequencing was performed by
MCLAB (Molecular Cloning Laboratories, ABD) (https://
www.mclab.com/DNA-Sequencing-Services.html) using
the MTHFR forward primer, and the sequencing result
was analyzed with CLC Main Workbench 8 software.
2.4. Determination of cell proliferation rate by MTT
assay
Assessing metabolic activity of BM-MSCs of each donor
was performed with triplicates and a control group. The
BM-MSCs (WT, HMZ and HTZ) were seeded into 1%
gelatin-coated F bottom 96-well with 10 × 103 cells/ well.
The incubation has been started for 24 h and 48 h at the

same time in a humidified atmosphere with at 5% CO2 at
37 °C. Ten microliters of MTT formazan dye, which was
used to indicate viable cells, was added into each well
after the incubation period. Four hours later, 100 uL of
solubilization buffer was added into each well to dissolve
insoluble formazan crystals and incubated in the dark
overnight. Dissolved formazan crystals provided a colored
solution for quantification by measuring the absorbance.
The absorbance values were obtained by Varioskan
instrument readouts and the results were statistically
analyzed with GraphPad Prism.
2.5. Investigating the colonization property by colony
forming unit-fibroblast assay
Colony-forming unit-fibroblast (CFU-F) assay has been
set up by coating the 6-well cell culture plates with 0.1%
gelatin (Sigma, 9391) and seeding the BM-MSCs of the
donors as to be 40 × 103 cells/well. The plates were prepared
as duplicates for all WT, HMZ and HTZ groups. The mix
of MSC Nutristem XF medium (Biological Industries,
05-200-1A) and MSC Nutristem XF Supplement was
freshened in every 3 days as prewarmed before using for 10
days. For colony detection, the colonies were stained with
Giemsa stain stock solution (Sigma G5637-5G) diluted
with 1X DPBS in 1:10 ratio. The cells in each well were
washed with 1X DPBS twice. Ice cold 99.9% methanol (0
°C) was added for fixation for 10 min. After incubation
time is over, methanol was aspirated and the plates were
left uncovered to let the remaining methanol to evaporate.
Giemsa working solution (1:10 diluted stock solution) was
added at a volume of 2 mL to cover the surface of the cells
in each well and incubated for 10 min at RT. The wells
were washed with plenty of ddH2O for 3 times until all
the dye residues were removed. For the quantitation, the
wells were imaged to calculate colony numbers and sizes
by using ImageJ (v. 1.53a) and the results were statistically
analyzed with GraphPad Prism.
2.6. Differentiation of BM-MSCs
2.6.1. Adipocyte differentiation of BM-MSCs
For the adipocyte differentiation, 6-well plates were
prepared by coating with 0.1% gelatin. The cells counted
with trypan blue solution were seeded into wells at a
density of 10 × 104 cells/well. The experimental set-up was
established with duplicates for each donor and one control
group which did not receive differentiation medium. The
cells were incubated in 5% CO2 incubator at 37 °C until
they reach at least 80% confluency, with the renewal of
the prewarmed MSC medium in every 2–3 days. The
combined StemPro Adipogenesis Differentiation Basal
Medium (PromoCell, C-28016) and StemPro Adipogenesis
Supplement (PromoCell, C-39816) were used to initiate the
adipogenesis of the cells reached the desired confluency.
The cells were cultured for 12 days and their medium
was changed with a fresh medium once in every 3 days.
At the end of the differentiation period, the medium was
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aspirated and washed with 1X PBS, then fixed with 4%
paraformaldehyde solution for 30 min at RT. The fixation
was ended by washing them with 1X PBS twice and with
ddH2O 3 times. After the washing process, the cells were
covered with OilRedO (Sigma O0625-25G) solution in
order to stain lipid droplets in differentiated cells for 50
min at RT. The cells were washed with ddH2O 3 times to
remove the dye residues. In the end, the cells were kept
with ddH2O in order to prevent them from drying until
their images were captured. For the photos, Zeiss AX10
microscope (Carl Zeiss, USA) was used. ImageJ (v. 1.53a),
the image processing program, was used for quantitation
based on stained lipid droplets of adipogenesis from the
collected photos.
2.6.2. Osteocyte differentiation of BM-MSCs
For the osteocyte differentiation, 6-well plates were
prepared by coating with 0.1% gelatin. The cells counted
with trypan blue solution were seeded into wells at a
density of 10 × 104 cells/well. The experimental setup was established with duplicates for each donor and
one control group which did not receive differentiation
medium. The cells were incubated in 5% CO2 incubator
at 37 °C until they reach at least 80% confluency, with the
renewal of the prewarmed MSC medium in every 2–3
days. The combined StemPro Osteocyte Differentiation
Basal Medium (PromoCell, C-28013) and StemPro
Osteogenesis Supplement (PromoCell, C-39813) were
used to initiate the osteogenesis of the cells reached the
desired confluency. The cells were cultured for 12 days
and their medium was changed with a fresh medium once
in every 3 days. At the end of the differentiation period,
the medium was aspirated and washed with 1X PBS, then
fixed with 70% ethanol for 1h at RT. Fixation was ended
by washing the cells with ddH2O twice. After the washing
process, the cells were covered with Alizarin Red-S (Merck
1062780025, pH 4,1-4,3) in order to stain calcium deposits
on differentiated cells for 30 min at RT in dark. Unbound
dye was washed with ddH2O 3 times. The stained cells were
kept with ddH2O in order to prevent them from drying
until their images were captured with Zeiss AX10 light
microscope (Carl Zeiss, USA). ImageJ (v. 1.53a) was used
for quantitation based on the stained calcium deposits of
osteogenesis from the collected photos.
2.6.3. Chondrogenesis differentiation of BM-MSCs
Before the initiation of chondrogenesis differentiation,
round-bottom (U bottomed noncoated and nonadherent)
96-well plates were used in order to facilitate sphere
formation at the density of 15 × 104 BM-MSCs during
the 48-h incubation in 5% CO2 incubator at 37 °C.
Chondrogenesis has been started with the combined
StemPro Chondrocyte Differentiation Basal Medium
(PromoCell, C-28012) and StemPro Chondrogenesis
Supplement (PromoCell, C-39812) with replacing with
the fresh prewarmed differentiation medium once in 3
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days. There were duplicates and a control group, which
was replaced with prewarmed MSC medium, used as
the experimental set-up and the process ended up after
the 21 days period. All the spheres were washed with 1X
PBS twice in order to remove the medium and fixed with
10% formalin for 60 min at RT. The fixed spheres were
washed with ddH2O twice and stained with Alcian Blue
(Sigma, TMS-010-C, pH 2.5) overnight at RT in a dark
place, covered with aluminum foil. To remove excess
dye, destain solution was added into each well for 10 min
twice and then the spheres were washed with 1X DPBS.
The chondrogenic differentiation was demonstrated by
capturing images of the spheres. Semiquantification was
also performed to indicate the experimental results.
Semiquantification was based on the Alcian blue
elution from the spheres. The absorbance measurement
via Varioskan readout of eluted Alcian blue demonstrated
the differentiation level of the cells. 8M Guanidine HCl
solution (GuHCl) was prepared to elute Alcian blue from
the spheres. The 1X PBS was removed and 150 uL/well
of 8M GuHCl was added into each well and incubated
overnight at 2–8 °C. The absorbance was read at 600 nm.
There were also control groups within the wells containing
only 8M GuHCl.
2.7. Statistical analysis
The data was indicated as the means +/– SD and analyzed by
GraphPad Prism (GraphPad Software, La Jolla, CA, USA).
One-way ANOVA with Tukey’s multiple comparisons test
(between multiple groups) was used to analyze and p <
0.05 was considered significant.
3. Results
3.1. Genotyping the C667T polymorphism
All BM-MSCs were genotyped by using restriction
fragment length polymorphism (RFLP) assay. The enzyme
cleavage of BM-MSC donors has been given different
sizes as base pairs. The wild type (WT) donor without
mutation was demonstrated with a single band at 389
bp. The homozygous mutated (HMZ) donors resulted in
2 bands with the size of 173 bp and 217 bp. Finally, the
heterozygous mutated (HTZ) donors resulted in 3 bands
with the size of 389 bp, 217 bp and 173 bp. The human
BNP gene PCR product was used as a positive control in
all reactions according to its Hinf1 recognition site in the
amplified region. The BNP product gives a single band with
the size of 366 bp. Hinf1 enzyme digests BNP PCR product
into 2 sequences with 229 bp and 137 bp (Figure 1). For
each genotype, one representative run was demonstrated
in RFLP results.
RFLP results were confirmed by performing Sanger
sequencing and sequencing results were analyzed by CLC
Workbench 8. MTHFR gene is on (–) strand of the genomic
DNA and the polymorphism we searched for is also
referred to as rs1801133. The samples were compared with
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Figure 1. Genotyping of BM-MSCs by RFLP assay. The demonstration of WT, HMZ and HTZ genotypes (respectively) by the
size of bands.

the NG_013351 coded genomic DNA sequence, obtained
from the NCBI genome browser. Since we used a forward
primer for sequencing, the mutation corresponded to the
218th nucleotide in the sequence by indicating the SNP
C677T as G >A change.
For the wild type donors when tracer data is followed,
it has been seen that G nucleotide is on the 218th base.
Since both alleles have G nucleotides, there is only one
trace data represented in black (Figure 2a).
For the heterozygous donors, the tracer data
demonstrates that there is A nucleotide as well as G
nucleotide is at the 218th base. Since both alleles have 2
different bases, there are two trace data represented by
black and green color which belong to the HTZ donors
(Figure 2b).
For the homozygous donors, the tracer data
demonstrates the G nucleotide is replaced by nucleotide A
at the 218th base. Both alleles have A nucleotide, there is
one trace represents the green color (Figure 2c).
Among all the samples sequenced 3 WT, 3 HTZ,
and 3HMZ were used in further experiments and one
representative tracer data was demonstrated in Figure 2.
3.2. Characterization of human BM-MSCs by flow
cytometry
The human BM-MSCs used in this study were previously
isolated and characterized by Acıbadem Labcell
(Acıbadem Health Group Co.). The characterization
was performed by using flow cytometry based on MSC
markers validated by ISCT (Dominici et al., 2006).The
flow cytometry results indicated that all the BM-MSCs
obtained from all donors expressed the MSC markers
over 95% which are CD73, CD90 and CD105. In addition
to that, as a negative demonstration, the hematopoietic
markers were also investigated. It was observed that the

hematopoietic markers, HLA-DR, CD34 and CD45, were
also not expressed by any of the hBM-MSCs. In all BMMSCs, the negative marker expressions were below 1%
(Figure 3, Table 2).
3.3. The effect of MTHFR C677T polymorphism on BMMSC morphology
The cells that evaluated for the morphological and
proliferative differences were at the passage number (P)
between 4 and 7. MTHFR C677T polymorphism did not
show any significant difference between the donors when
heterozygous and homozygous donors compared to wild
type donor under the light microscope (Figure 4). That is
why we wanted to further evaluate the effect of MTHFR
C677T SNP in their proliferation potentials.
3.4. The effect of MTHFR C677T polymorphism on BMMSC proliferation
The MTT assay was applied to all 3 biological replicates
from each genotype and 3 technical replicates from each
sample for both 24 h and 48 h with 10,000 cells/well in 96well plates. The MTT results were plotted with GraphPad
Prism and no significant difference was found (Figure
5) (p values for 24 h and 48 h are 0.4597 and 0.7824,
respectively). The comparative 24-h p values between WTHMZ, WT-HTZ, HTZ-HMZ were 0.8619, 0.5475, 0.9271,
and 48-h p values were 0.9860, 0.8765, 0.9751, respectively.
The analysis was performed by using Tukey’s multiple
comparison test between allelic groups.
3.5. Evaluating the effect of MTHFR C677T
polymorphism on BM-MSCs by colony-forming unitfibroblast (CFU-F) assay
Colony-forming unit-fibroblast (CFU-F) assay is one of
the main characterizations of MSCs. the cells were seeded
as 40 × 103 cells/ well in 6-well plates and cultured for 10
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Figure 2. Representative Sanger sequencing results of the BM-MSCs. a) The representation of
assembly of the WT 1. b) The representation of assembly of the HTZ 1. c) The representation of
assembly of the HMZ 2.

Figure 3. Representative flow cytometry image of BM-MSC surface marker characterization.
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Table 2. BM-MSC marker expressions of the donors.
CD73 (%) CD90 (%) CD105 (%)

HLA-DR (%)

CD34 (%) CD45 (%)

WT1

99.8

99.9

99.8

0.1

0.2

0.1

WT2

99.9

99.9

99.7

0.1

0.1

0.1

WT3

99.8

99.7

99.9

0.1

0.1

0.1

HTZ1

99.7

99.3

99.7

0.2

0.1

0.1

HTZ 2

96.4

95.5

96.6

0.1

0.1

0.1

HTZ 3

99.8

99.4

99.5

0.3

0.7

0.1

HMZ 1

99.8

99.9

99.1

0.1

0.1

0.1

HMZ 2

99.7

98.0

99.5

0.1

0.1

0.2

HMZ 3

99.3

99.8

99.5

0.1

0.7

0.1

Figure 4. The morphology of BM-MSC donors under the light microscope. a) Wild-type (WT). b) Heterozygous
(HTZ). c) Homozygous (HMZ).

Figure 5. MTT assay results of BM-MSCs for 24 h and 48 h.

days. The images of Giemsa stained colonies were analyzed
by using ImageJ and a significant difference between WTHTZ CFU numbers was revealed by using GraphPad Prism
(p = 0.093) (Figure 6). However, there was no significant

difference between HTZ-HMZ and WT-HMZ (p values
were 0.4430 and 0.1024, respectively). The analysis was
performed by using Tukey’s multiple comparison test
between allelic groups.
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Figure 6. Relation between MTHFR mutation and
CFU of BM-MSCs. As a result of quantitation by
ordinary one-way ANOVA test (GraphPad Prism),
the comparison of colony numbers showed a
significant difference between WT-HTZ genotypes
(p = 0.093) (**). p values of comparison of WT-HMZ
and HTZ-HMZ are 0.4430 and 0.1024, respectively
(p < 0.05).

3.6. The effect of MTHFR C677T polymorphism on
adipogenic differentiation of BM-MSCs
Adipogenic differentiation experiments were visualized
(Figure 7a) and quantified based on the presence of
red lipid droplets in the staining area. As a result of
quantification by using GraphPad Prism, there was a
significant difference between WT-HMZ (p = < 0.0010)
(**) genotypes while there was not any significant
difference between WT-HTZ and HTZ-HMZ genotypes
(p values were 0.0795 and 0.1816, respectively) (Figure
7b). The analysis was performed by using Tukey’s multiple
comparison test between allelic groups.
3.7. The effect of MTHFR C677T polymorphism on
osteogenic differentiation of BM-MSCs
Osteogenic differentiation experiments were visualized
(Figure 8a) and quantified based on the presence of calcium
deposits in the staining area. As a result of quantification by
using GraphPad Prism, there was no significant difference
between WT-HMZ, WT-HTZ and HTZ-HMZ genotypes
(Figure 8b). The analysis was performed by using Tukey’s

Figure 7. The results of adipogenic differentiation assay. a) The light microscopy images of BM-MSCs after adipogenic differentiation
stained with Oil Red O (WT, HTZ and HMZ, respectively). b) Quantification of adipogenic differentiation assay by one-way ANOVA
with Tukey’s multiple comparison test. Significance difference between WT-HMZ genotypes (p = < 0.0010) (**) (p < 0.05). There was
not any significant difference between WT-HTZ genotypes (p = 0.0795) and HTZ-HMZ (p = 0.1816).
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Figure 8. The results of osteogenic differentiation assay. a) The light microscopy images of BM-MSCs after adipogenic
differentiation stained with Alizarin Red-S dye (WT, HTZ and HMZ, respectively). b) Quantification of osteogenic
differentiation assay by one-way ANOVA with Tukey’s multiple comparison test. There was not any significant
difference between WT-HTZ (p = 0.999), WT-HMZ (p = 0.7041) and HTZ-HMZ (p = 0.6952).

multiple comparison test between allelic groups; WTHTZ, WT-HMZ and HTZ-HMZ (p values were 0.9999,
0.7041 and 0.6952, respectively).
3.8. The effect of MTHFR C677T polymorphism on
chondrogenic differentiation of BM-MSCs
Chondrogenic differentiation was visualized (Figure 9a)
and all allelic groups have important differences between
their biological replicates and there were differences
between each other according to Alcian blue staining.
Semiquantification results, performed by measuring
the OD600nm absorbance value, demonstrated that there
was no significant difference between allelic groups (Figure
9b). The analysis was performed by using Tukey’s multiple
comparison test and the comparative p values of WT-HTZ,
WT-HMZ, and HTZ-HMZ are 0.7313, 0.5691, and 0.1620,
respectively. However, it was also noticed that the HMZ
groups were poorly differentiated into chondrocytes.
4. Discussion
In our study, we investigated the effect of MTHFR C677T
polymorphism on BM-MSCs. We obtained remarkable

results specifically for the effect of the polymorphism
on the adipogenic differentiation potential of the cells.
There are several studies demonstrated the underlying
defects of the differentiation mechanism. It was reported
that adipogenesis increased when folate metabolism was
inhibited or S-adenomethionine inhibitors were used.
It was deduced that the decrease in DNA methylation
profile is the reason of increased adipogenesis (Gouffon,
2012). These kinds of defects in folate metabolism can be
emerged by a mutation on the MTHFR gene like MTHFR
C677T polymorphism. Di Renzo et al. (2014) reported that
MTHFR C677T polymorphism was found to be directly
proportional to the increase in body fat mass and decrease
in muscle ratio, and they showed that obese patients
with metabolic syndrome could lose weight rapidly with
a hypocaloric diet. Despite all these studies, changes
in differentiation cannot be explained by the MTHFR
gene alone according to the report by (Nic-Can et al.,
2019) which demonstrates the importance of epigenetic
factors on differentiation potential of MSCs. Despite
the differences in standard deviations, our findings also
support the current findings in the literature.
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Figure 9. The results of osteogenic differentiation assay. a) The light microscopy images of BM-MSCs after
adipogenic differentiation stained with Alcian blue dye. b) Quantification graph by using ordinary one-way
ANOVA with Tukey’s multiple comparison test. There was no significant difference between WT-HTZ (p =
0.7313), WT-HMZ (0.5691) and HTZ-HMZ (p = 0.1620) genotypes.

MTHFR C677T polymorphism and its relation
with bone related-diseases is known and this relation
has been reported previously (Villadsen et al., 2005).
High homocysteine (Hcy) levels due to MTHFR C677T
polymorphism cause some disorders in the bone.
For this reason, our negative findings in osteocyte
differentiation can be explained by in vitro conditions,
where no continuous homocysteine accumulation is
present. MTHFR polymorphism, which causes longterm homocysteine induced damage in physiological
conditions cannot be provided in vitro. As a result, the
C677T mutation may not directly affect the osteogenic
differentiation potential of BM-MSCs in our experimental
setup.
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The last investigation for the differentiation ability
was the chondrogenic differentiation assay and there was
no significant result. All allelic groups had important
differences between their biological replicates. It was
clearly observed that HMZ genotype replicates did not
respond to the chondrogenic differentiation despite the
experimental repeats. This can be explained according
to the report demonstrated that the T allele frequency is
increased in osteoarthritis patients with MTHFR C677T
polymorphism compared to healthy individuals. It is
also reported that the patients with osteoarthritis were
observed 6 times more with homozygous TT genotype
(Inanir et al., 2013). In another study, it is demonstrated
that epigenetic regulation of the WISP1 gene plays an
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essential role in cartilage degeneration in osteoarthritis
patients. Both hyper- and hypomethylation of this gene
take place in cartilage differentiation (van den Bosch et
al., 2015). These two studies can be an explanation of our
results. Our HMZ genotype replicates did not differentiate
according to the possibility of inhibition of methylation
due to MTHFR mutation. This may have caused the
changes in the regulation of important genes in cartilage
differentiation.
Runx2 is an important transcription factor that plays a
role in both osteogenic and chondrogenic differentiation.
A study reported that there are multiple functions of Runx2
in the regulation of chondrogenic differentiation. It plays
a role in the maintenance of chondrocyte phenotype while
inhibiting adipogenesis. In the study, they depleted the
Runx2 and observed the loss of differentiated phenotype
of chondrocytes (Enomoto et al., 2004). In our study even
though we did not check the levels of Runx2, we observed a
significant increase in HMZ adipogenic differentiation and
almost no differentiation in chondrogenic differentiation
setup. That is why the expression levels of Runx2 could
be investigated in further experiments. It must also be
considered that MTHFR gene might not be the only reason
that affects the differentiation potential due to donors’
background genetic mutations.
When the CFU-F results were considered a significant
difference between WT and HTZ allelic groups was
obtained. This result can be concluded according to the
essential role of MTHFR protein in folic acid metabolism
and in methylation/remethylation cycles. With the C677T
mutation, the protein gains a heat-labile structure and its
activity decreases by 35% in heterozygous genotype and
50%–70% in homozygous genotype. In the presence of
this mutation, proliferation or cellular morphology was
not affected, but a significant decrease in HTZ genotype
may be explained by a change in the balance of progenitor
and stem cells. It is known that DNA methylation and
demethylation processes play an important role in stem
cell differentiation. On the other hand, in HMZ cells, since
the methylation cycle is not sufficiently well established,
spontaneous differentiation or the number of progenitor
cells may be decreased and the number of stem cells
may be more preserved. For this reason, there may not
be a significant difference between WT-HMZ. In order
to prove this inference, epigenome differences need to
be investigated. In a study investigating the relationship

between oral epithelial cells and MTHFR C677T mutation,
the result was controversial although there was no
difference in global methylation levels.
Finally, our results did not find any significant difference
in the proliferative potential of the cells in the presence
of MTHFR C677T mutation. The morphology and the
CD marker signature of the cells were not different from
the WT, but the cells demonstrated the most important
difference at the adipogenic differentiation potential of
BM-MSCs
We have investigated the effect of MTHFR C677T
polymorphism on BM-MSCs because the MTHFR gene
was related with a wide range of different diseases such
as coronary artery and cardiovascular diseases, psoriasis,
infertility, Parkinson’s disease, Alzheimer’s disease,
osteoporosis, diabetes mellitus, cancer, etc. Moreover, we
have only investigated the adipogenic, osteogenic and
chondrogenic differentiations but neural differentiation is
still needed to be investigated as there is a relation between
MTHFR C677T polymorphism and neural diseases.
In summary, this study demonstrates MTHFR C677T
polymorphism affects adipogenic differentiation capacity
and the clonality of the BM-MSCs. It is possible that
there can be many other mutations that take place in the
genome of the donors. Considering that every individual
has a different genome, screening of donor cells with
whole genome sequencing (WGS) or at least panels of
known important mutations before cellular transplants
can provide important information about the treatment
effectiveness and efficiency, which must be supported
with further studies. The success of the therapy and the
future wellbeing of the patients are the final desire of both
the clinicians and the patients. We believe that our study
would contribute to the importance of possible effects of
genetic mutations on the cells used for cellular therapies.
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